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51. Abstract
Th e aim of this thesis was to develop a new simple method for measuring 
added caesium (Cs) in blood plasma and to use it in the study of short-time 
plasma kinetics.
Th e new method, based on isotopic dilution, is analogous to radioim-
munoassay. Th e dispersive complex salt ammonium-iron(III)-hexa cyano-
ferrate(II) (AFCF) has a very high affi  nity towards Cs+. In a mixture of 
plasma, AFCF and added radioactive Cs tracer (134Cs), the amount of 
AFCF-bound activity depends on the amount of stable Cs in plasma. Th is 
bound activity is separated from soluble activity by co-precipitating AFCF 
with plasma proteins using trichloroacetic acid and measured using a 
standard gamma counter. Using standard samples prepared from plasma 
collected prior to an intravenously given Cs dose, the Cs concentration in 
plasma samples aft er the dose can be determined. Th e qualitative detec-
tion limit for the method is around 0.2 μmol l-1, and the practical limit for 
quantitative results around 1 μmol l-1. 
Using this method, short-term plasma kinetics after an intravenous 
dose of Cs was measured in both goats and horses. Th e values measured for 
goats were very similar to those using 134Cs as a tracer in another study.
Th e rate constant for the removal of Cs from the bloodstream was ini-
tially above 0.1 min-1, but decreased within 40 min to a value below 0.02 
min-1. From 2 to 40 min, the plasma concentration can be approximated 
with a biphasic exponential decay curve. Exercise speeds up the rate of Cs 
removal from blood. Between 30 and 40 min aft er the start of exercise, the 
rate of Cs removal was twice as high in exercising individuals compared 
to resting individuals (0.06 min-1 vs. 0.03 min-1). Stimulation of muscle 
sodium-potassium pumps (Na, K-ATPase) is a plausible explanation for 
the increased removal of Cs from blood during exertion. 
At 30 min aft er dosing, the tissues with the highest 134Cs content were 
the gastrointestinal tract (22% of original dose), skeletal muscle (14% of 
dose) and the kidney (13%). A likely location for the large unrecovered 
portion of the original dose (38%) was connective tissue. Incorporation in 
one or several of these tissues probably explains the rapid initial removal 
of Cs from circulation.
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84. Introduction
Due to the central role of radioactive caesium (Cs) isotopes in nuclear 
fall-out, the long-term distribution and kinetics of Cs in animal tissues 
have been studied intensely, especially in the 1950s and 1960s (Stara et al., 
1971). Th ese studies, mostly involving experimental animals, concentrated 
on the medium-term (days) and long-term (weeks) distribution following 
chronic oral administration. Th e data collected have been useful in the as-
sessment of risks caused by food and feed contaminated with nuclear fall-
out (Howard & Howard, 1997; Voigt, 1997).
Another biologically interesting aspect of Cs is its interaction with cel-
lular potassium (K) transport proteins, which have been elucidated mainly 
using diff erent in vitro techniques (Draber & Hansen, 1994; DiFrancesco, 
1995; Ussing et al., 1996; Schornack et al., 1997; Th ompson et al., 2000). 
Th ese studies, among others, have been helpful in elucidating the transport 
processes of both K and Cs.
Blood plasma, together with interstitial fl uid (ISF), is the connecting 
element between all cells in the body. As a small ion, Cs+ moves readily 
between plasma and ISF. Th us, processes transporting Cs+ in and out of 
cells are likely to be mirrored as changes in plasma Cs concentration. Since 
the same transport processes are involved in the transport of K, following 
the kinetics of plasma Cs might be useful in the study of K transport proc-
esses in vivo. It must be remembered, however, that the atomic mass of Cs 
(132.9 u) is more than three times larger than that of K (39.1 u). Th e ionic 
radius of Cs+ is also considerably larger than that of K+ (Table 1). Diff er-
ences in the kinetic behaviour of the two alkali metal ions are therefore to 
be expected.
Although the long-term kinetic behaviour of Cs can generally be ex-
plained using cell-level mechanisms, insuffi  cient information exists to 
explain all peculiarities involved in kinetics on the whole-animal level. 
Studies on the short-term kinetics of Cs, i.e. the development of tissue con-
centrations within an hour or so aft er application, are therefore warranted. 
Th is information is needed for the estimation of the rate of entry of Cs into 
tissues, whereas long-term changes refl ect better the balance between en-
try and exit of Cs. Th is thesis presents results from the studies of the short-
term kinetics of Cs in goats and horses. In the latter species, the eff ect of 
exercise on Cs plasma kinetics was also investigated.
To examine plasma Cs kinetics, several traditional methods are avail-
able. On a purely technical basis, gamma-emitting radioactive isotopes of 
Cs are ideal since they are easy to measure and their low Cs carrier concen-
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9tration is certain not to cause gross interference with physiological proc-
esses. However, radiohygienic considerations limit the use of long-lasting 
and accumulating radioactive isotopes in animal experiments, especially 
in non-terminal experiments with larger animals. Th e toxicity of stable Cs 
(133Cs) is relatively low, with an LD50 in the range of 10 mmol kg-1 (Johnson, 
et al., 1975; Pinsky & Bose, 1984). Th us dosing and measurement of trace 
levels of stable Cs could be another way of obtaining information about 
the biological behaviour of Cs. However, the measurement of stable Cs, 
especially in the micromolar region, involves equipment and know-how 
not available in standard biological or biochemical laboratories. Here, a 
novel, simple and inexpensive method for the assay of added stable Cs in 
blood plasma is presented and used in practical studies. Th e method is 
based on the competitive binding of stable and radioactive Cs isotopes into 
ammonium ferric cyanoferrate (AFCF), a complex salt with a high specifi c 
affi  nity towards Cs (Giese & Hantzsch, 1970; Arnaud et al., 1988; Giese, 
1988; 1989).
Introduction
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5. Review of the literature
5.1. Caesium chemistry and physics
Th e term “caesium” comes from the Latin word “caesius”, meaning sky 
blue. Th is name is due to the intense blue colour (λ = 456 nm), emitted by 
the element when heated in a gas fl ame. 
Like other alkali metals, Cs is very electropositive, existing in aqueous 
solution only in its most positive oxidation state (+I). Among the stable 
alkali metals, Cs has the largest crystal ionic radius (Table 1). However, 
the mobilities of K, Rb and Cs in an electric fi eld in aqueous solution are 
almost the same (Table 1), indicating that the size of the hydrated ions of 
these elements is similar. 
Cs has only one stable isotope (133Cs). General literature presents 49 radio-
isotopes with a mass number between 112 and 151 (Anonymous, 2005). 
Naturally, most of these have a rapid decay rate. Only three radioactive Cs 
isotopes have a half-life of over two weeks:
Table 1. Crystal ionic radius (Shannon, 1976) and mobility 
(Bell & Lott, 1972) of alkali metal cations.
Li+ Na+ K+ Rb+ Cs+
Crystal ionic radiusa (pm) 76 102 138 152 167 
Mobility (m2s-1V-1 x 10-9) 40 52 76 79 80
aco-ordination number VI
Nuclide Half-life (years) Energies of major emitted particles (keV)
  β- (max.) γ
134Cs  2.1  658   605, 796 
135Cs  2.3 x 106 269    -
137Cs  30.2  514   662
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 Of these, 137Cs and 135Cs are accumulated in large quantities (ca. 6%) in 
the beta decay processes following fi ssion of the common fi ssile nuclides 
235U and 239Pu. Both of these Cs isotopes are therefore found in nuclear 
waste and fallout from nuclear explosions. 135Cs is a pure beta-emitter with 
a specifi c activity some fi ve orders of magnitude less than 137Cs. Because 
activity measurement of 135Cs is diffi  cult and its activity in samples is neg-
ligible compared with that of 137Cs, the nuclide is usually ignored in radio-
chemical measure ments. Although 134Cs is also a fi ssion product, its yield is 
very low (ca. 0.01%). However, considerable amounts accumulate in fi ssile 
nuclear fuel, due to the activation of 133Cs by slow neutrons. Th e activity 
ratio 134Cs/137Cs in the fall-out of the Chernobyl accident, for example, was 
around 0.55 (Mück et al., 2002). Th e annual oral limit of intake (ALI) for 
134Cs is 1 MBq and for 137Cs 2 MBq. For dose estimation following oral in-
take 19 nSv Bq-1 for 134Cs and 13 nSv Bq-1 for 137Cs are used (International 
Commission on Radiological Protection, 1991).
Th e binary salts of Cs, like those of other alkali metals, are highly solub-
le in water. However, certain insoluble complex hexacyano ferrates have 
proven to be specifi c agents for the removal of Cs from solution (Streat & 
Jacobi, 1995). Th ese complex salts have the general structure of 
X2MeII[Fe(CN)6] or XMeIII[Fe(CN)6],
where X denotes a monovalent entity (alkali metal or ammonium), MeII 
a metal with an oxidation state of +II and MeIII a metal with an oxida-
tion state of +III. Cs cations tend to replace the monovalent entity in the 
complex, rendering Cs insoluble. For example, insoluble potassium cobalt 
hexacyanoferrate (K2CoFe(CN)6) has been used to decontaminate coolant 
waters in atomic power plants (Lehto & Harjula, 1999). 
Especially interesting from the viewpoint of this thesis are the salts in 
which MeIII is an iron. Th ese salts are oft en referred as “Prussian Blue”-
compounds. Unfortunately, there is some ambiguity regarding this no-
menclature. Traditionally, the term “Prussian Blue” (PB) has been used for 
two complex compounds:
KFe[Fe(CN)6]  “soluble Prussian Blue”
Fe4[Fe(CN)6]3 “insoluble Prussian Blue”
Th e latter lacks potassium ions and does not readily form colloidal dis-
persions, unlike the former. Th ese dispersions are not, however, true solu-
tions. Th e colloidal crystals can be separated from the dispersion using, 
for example, ultrafi ltration. 
Because of their affi  nity towards Cs and lack of toxicity (Pearce, 1994), 
PB compounds have been used as a feed additive to reduce the contamina-
tion of radioactive Cs from nuclear fall-out in animals. Nigrovic (1963) 
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found that Fe4[Fe(CN)6]3 given to rats orally both reduced the incorpora-
tion and accelerated the decorporation of 137Cs. Richmond and Bunde 
(1966) also observed an increased decorporation of 137Cs in rats receiving 
PB. Th e authors did not publish the structure of the PB that they used, 
but since it was given together with drinking water, it is reasonable to as-
sume that the compound was “soluble” PB (KFe[Fe(CN)6]). Müller et al. 
(1974) reported that this “soluble” PB was more eff ective in the decor-
poration of 137Cs than “insoluble” PB (Fe4[Fe(CN)6]3). Giese & Hantzsch 
(1970) compared the eff ect of diff e rent soluble PB compounds and found 
out that, among others, ammonium–iron(III)–hexacya no fer rate(II) 
(NH4Fe[Fe(CN)6]) was significantly more effective in binding 137Cs in 
the alimentary tract than traditional soluble PB (KFe[Fe(CN)6]). Moreo-
ver, the authors noticed that, unlike other PB-com pounds containing 
monovalent ions, CsFe[Fe(CN)6] does not readily form colloidal disper-
sions. CsFe[Fe(CN)6] was also not very eff ective in binding 137Cs. Th e au-
thors proposed the existence of a “solubility trap”: when 137Cs undergoes 
exchange with a monovalent ion in the PB-compound, a less dispersive 
complex forms, which reduces desorption of bound 137Cs. 
Aft er the nuclear accident in Chernobyl, ammonium–iron(III)–hexa-
cya no fer rate(II) was approved as a feed additive for reducing the incor-
poration of radioactive Cs from contaminated feed (Giese, 1989). In the 
literature, the abbreviation AFCF is oft en used for the compound, short for 
ammonium ferric cyano ferrate (Arnaud et al., 1988). Due to the manufac-
turing process, the commercial product contains approximately 30% (by 
weight) ammonium chloride (NH4Cl). 
5.2. Caesium biology 
No biological function has been found for Cs. To a certain degree, however, 
its cellular behaviour resembles that of K. Th us, it makes sense to compare 
these two elements when reviewing Cs biology. 
Like K, the absorption of soluble Cs from the gastrointestinal tract is 
fast and almost quantitative, and it most likely occurs through paracellular 
transport (Nedergaard et al., 1999). However, certain feed stuff s, particu-
larly non-digestible fi bre, adsorb Cs and can reduce its absorption (Giese, 
1971). In blood plasma, Cs exists as a free ion, just like potassium and 
sodium. Th is has been shown experimen tally; the ultrafi ltratation of 137Cs-
containing plasma resulted in an ultrafi ltrate with 94% of the original ac-
tivity (Liubashevskii, 1968).
Th e membrane potential results in the passive fl ow of all permeable 
cations into the cell, until the Nernst equilibrium is reached. For univalent 
cations, like Cs+, this equilibrium means a trans mem brane concentration 
ratio near that of K, with an intracellular concentration some 20 to 40 ti-
13Review of the literature
mes higher than extracellular concentration. In rats, tissue/plasma ratios of 
this magnitude were reached in most internal organs within 2 h of intrave-
nous administration of 134Cs (Gregus & Klaassen, 1986). Th is passive trans-
port is facilitated by the numerous diff erent kinds of potassium channels 
on cell membranes. Cs permeability varies depending of the channel type. 
According to Leggett et al. (2003), the Cs/K selectivity ratio for K channels 
ranges from less than 0.02 to approximately 0.2. In fact, Cs is oft en used as 
a potassium channel blocker in in vitro work (Clay & Shlesinger, 1984). 
In addition to passive transport by the electrochemical gradient, Cs is 
pumped actively into cells by Na,K-ATPase, along with K. In general, this 
potassium transport protein discriminates Cs less than potassium chan-
nels. According to a review by Leggett et al. (2003), the typical Cs/K se-
lectivity ratio for Na,K-ATPase is 0.25. Experiments with Na,K-ATPase 
inhibitors indicate that Na,K-ATPase is almost solely responsible for the 
inward cellular transport of Cs in the rat heart (Schornack et al., 1997), 
frog sartorius muscle (Beauge & Sjodin, 1968) and frog skin epithelium 
(Ussing & Lind, 1996) . Th is may not be universal, however, as in rat soleus 
muscle as much as 28% of Cs uptake remained aft er addition of ouabain, 
a common Na,K-ATPase inhibitor (Dorup & Clausen, 1994). In the long 
run, the tissue/plasma ratio exceeds that of K in just about all soft  tissues 
(Relman et al., 1957; Bretfeld et al., 1968; Kernan, 1972). Obviously, the in-
ward active potassium transport processes of the cell membrane discrimi-
nate caesium less than the outward passive transporting processes.
Due to the release of radioactive Cs into the environment in nuclear 
atmospheric explosions, the whole-body retention of ingested Cs by dif-
ferent animals received much attention in the 1950s and 1960s. Usually, a 
three-component exponential function is needed for the exact description 
of body retention (Stara et al., 1971). Each of these components has a char-
acteristic half-life. For animals with similar feed and gastrointestinal physi-
ology, the half-life of the slowest component is a function of body mass. On 
a double logarithmic scale (log-log), the plots of half-lives and typical body 
weights of non-ruminants fall practically on one line. Th e values for rumi-
nants form another line, with their half-lives being considerably shorter 
than those of non-ruminants (Stara et al., 1971). In cows, for example, the 
half-life of the slowest compartment is around 20 days, whereas in humans 
it is around 110 days. Pigs are an exception, since their plot falls on same 
line as ruminants. In some studies concerning radioactive Cs retention, a 
single value for half-life is used to describe the time required for excretion 
of 50% of a single dose. Th e following values were collected by Shannon et 
al. (1965):
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Species Half-life (days)
Mouse   1.2
Rat   6.5
Dog   25
Pig   26
Goat   31
Human   110
Th e diff erent ways of interpreting the term “half-life” must be kept in mind 
when analysing data from the literature. However, since the eff ective half-
life of Cs in larger animals is measured in weeks, excretion is not likely 
to be a signifi cant factor when studying the short-term kinetics of Cs in 
plasma. 
Due to diff erences in cell types and blood fl ow, marked variation of Cs 
uptake and release in diff erent organs exists. Leggett et al. (2003) devel-
oped a biokinetic model (henceforth the “Leggett model”) for the retention 
of Cs in human organs and tissues, in which they used the following data 
for each organ or tissue:
 
 Steady state Cs content in humans (fraction of total body Cs)
 Blood fl ow (fractional cardiac output) 
 Tissue specifi c extraction fraction of Cs
Th e extraction fraction is defi ned as the fraction of atoms extracted by the 
organ/tissue in passage from arterial to venous plasma. Exact data for this 
quantity were unavailable, so the authors made well-founded estimations 
based on indirect data for Cs, K and Rb. Th eir estimates for the extraction 
fractions for diff erent organs/tissues were as follows:
 Kidneys, gastrointestinal tract, heart   0.2
 Liver, skin     0.05
 Brain      0.002
 All other tissues     0.1
Based on these estimates, the authors calculated the transfer coeffi  cients 
for Cs between diff erent organs/tissues and plasma, both for uptake and 
release. In general, the predictions based on the Leggett model seem to 
agree fairly well with empirical observations of Cs kinetics in diff erent tis-
sues (Leggett et al., 2003). 
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Some of the estimates based on the Leggett model are presented in Table 
7. As can be seen, in kidneys the rate of both uptake and release of 
Cs is very high. In muscle, on the other hand, the diff erence between the 
transfer coeffi  cients is huge, which is consistent with the observed high 
proportion (80%) of total body Cs in muscle in a steady-state situation. It 
is therefore not surprising that muscular dystrophies signifi cantly decrease 
Cs retention in humans (Lloyd et al., 1968, 1973). Guinea pigs suff ering 
from hereditary muscular dystrophy accumulate signifi cantly less 134Cs in 
their muscles than healthy control animals (Szentkuti et al., 1976). Th is 
also holds true also for swine with a defi ciency of selenium and vitamin E 
(Szentkuti, 1976) 
Cs is excreted through both urine and faeces. In carnivores, the major-
ity of Cs is excreted in urine (Hood & Comar, 1953; Mraz et al., 1958). 
In humans, the reported urinary fractions (ratio of cumulative urinary 
Cs to cumulative total Cs excretion) have varied from around 0.7 to more 
than 0.9, with an average value of approximately 0.86 (Leggett et al., 2003). 
However, considerable reabsorption of fi ltered Cs occurs in the kidneys. 
According to the Leggett model, the transfer coeffi  cient from the kidneys 
to the urinary bladder is only 1.7 day-1, compared with 32 day-1 from the 
kidneys to blood plasma. Due to the high degree of reabsorption, the ex-
cretion rates of Cs are modest. Lloyd et al. (1973) measured urinary clear-
ance values for Cs ranging from 2.8 to 4.6 plasma volumes d−1 in fi ve male 
subjects. Th e values according to the Leggett model in the same circum-
stances were between 3.5 and 3.9 plasma volumes d−1 (Leggett et al., 2003). 
Aldosterone, which stimulates the excretion of K, also increases the rate of 
removal of Cs from rats (Alli-Balogun, 1975). Adrenalec tomy, on the other 
hand, increases the retention of 134Cs (Feurer, 1976). Lowered aldosterone 
levels have also been proposed to be the reason behind the increased body 
half-life of 134Cs at high altitudes (Rundo & Richmond, 1970).
Although carnivores excrete less in faeces than in urine, considerable 
circulation of Cs occurs between the gastrointestinal tract and plasma. Th is 
can be inferred from the observation that oral application of insoluble Cs 
binders (e.g. Prussian Blue) considerably reduces the retention of body 
Cs. Melo et al. (1998) concluded that oral administration of PB reduced 
the long-term retention half-life by an average of 69%. However, there 
are many kinds of secretory and absorptive processes in the gastrointesti-
nal tract, and the exact pathways for this circulation between the plasma 
and the gastrointestinal tract have not yet been elucidated. In the Legget 
model, the gastrointestinal tract is assumed to receive Cs from saliva, gas-
tric juices, cells sloughed from the gastrointestinal tract walls, secretions 
through the walls of the small and large intestines, pancreatic juices, bile 
and Brunner’s gland secretions (Leggett et al., 2003). Using the normal as-
sumptions pertinent to the model, the calculation of transfer coeffi  cients 
between plasma and the contents of the stomach, small intestine and gas-
16 Review of the literature
trointestinal tract results in fi gures of 4.5, 1.0 and 0.02 day-1, respectively. 
Th e transfer coeffi  cient in the other direction, from small intestine to 
plasma, was 28 day-1. When this transfer coeffi  cient was assumed to be 
zero, the long-term retention half-life reduced by 60%, which is similar to 
the eff ect reached when using eff ective Cs binders.
Feed fi bre also binds Cs. Increasing the feed fi bre content considerably 
increases the proportion of Cs excreted in faeces compared to that excreted 
in urine (Mraz & Patrick, 1957a; 1957b). Th is diff erence in the structure 
is a likely explanation for the high ratio of faecal to urinary excretion in 
ruminants compared with non-ruminants. Th ese aspects have been exten-
sively discussed by Giese (1971). 
Little data exists in the literature on plasma Cs kinetics, especially short-
term kinetics. Ekman (1961) followed the plasma kinetics of 137Cs in goats 
for 14 days following a single oral dose. However, during the fi rst day only 
six samples were taken and measured. Possibly due to diff erences in gas-
trointestinal absorption, the time of maximum plasma concentration in 
diff erent animals varied from 30 minutes to 6 hours. Th us, the experiment 
did not shed much light on the short-term plasma kinetics of Cs. Poe 
(1972) compared the plasma kinetics of 131Cs and 42K in dogs aft er an intra-
venous dose for 3 h, with sample frequency varying from 5 to 20 min. Th e 
author found the plasma concentration curve to be multiphasic, contain-
ing three basic components. At 2 min aft er the dose, 42% of the adminis-
tered 131Cs was still in the blood, whereas at 60 min only 3.8% remained. 
42K vanished much faster from the circulation, with 22% and 1.6% of the 
original dose remaining in blood at 2 and 60 min, respectively. 
Cellular intake is not necessarily the only way to incorporate Cs. Using 
autoradiographic techniques, Nelson et al. (1961) found that following an 
intravenous injection the initial uptake of Cs in murine cartilage was very 
pronounced. Th e authors suggested ion exchange as a mechanism for this 
uptake. Th ere are also indications that the tendinous fraction from beef 
muscle has a much greater affi  nity to 134Cs than muscle homogenate as a 
whole (Szentkuti & Giese, 1974).
Within cells, Cs tends to distribute unevenly. In many diff erent types 
of cells, a large fraction of Cs was found within the nucleus or fi xed to 
the nuclear membrane 24 hours aft er an oral dose (Giese and Rekowski, 
1970). Using autoradiography, in myofi brils, 134Cs was shown to attach at 
distinct distances similar to those between isotropic and anisotropic bands 
Szentkuti & Giese (1973). With the help of transmission electron micro-
scopy, Edelmann (1980) confi rmed that Cs, together with K and Rb, ac-
cumulates preferentially in the A-band and, to a lesser extent, the Z-disc 
of myofi brils. Edelmann’s results have been used to champion the associa-
tion-induction hypothesis as an explanation for biological electrochemical 
gradients (Ling, 2005). Th is hypothesis has not, however, gained wide ac-
ceptance in the scientifi c community (Edelmann, 2005). 
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In a two-week chronic feeding experiment with rats, muscles rich in red 
fi bres (type I) accumulated signifi cantly more Cs than muscles contain-
ing predominantly white fi bres (type II) (Kernan, 1969). Th e K+ effl  ux in 
electrically stimulated type I muscles is considerably less than in type II 
muscles (Clausen et al., 2004). Th us the diff erence in net Cs accumulation 
between the two muscle types may be due to diff erences in the rate of Cs+ 
effl  ux.
Th e concentration of endogenous stable Cs (133Cs) in biological sam-
ples is extremely low. In human soft  tissue, the concentration of Cs is gen-
erally in the range of 2-50 ppb (Yamagata, 1962; Iyengar et al., 2004). In 
blood plasma, the concentration is even lower, around 1 ppb (Versieck 
et al., 1977). Since the LD50 of Cs is approximately 1g/kg (Johnson et al., 
1975; Pinsky & Bose, 1984), toxic amounts of Cs can not be ingested from 
natural sources. However, some cancer patients treat themselves with large 
amounts of CsCl, which can lead to symptoms of poisoning (Saliba et al., 
2001; Lyon & Mayhew, 2003; Dalal et al., 2004). Th is unoffi  cial self-treat-
ment is based on some reports published in the 1980s indicating Cs to have 
tumor-repressing activity (El-Domeiri et al., 1981; Sartori, 1984a; Tuft e 
et al., 1984). However, no well-founded clinical tests on the anti-cancer-
properties of Cs are available. Moreover, the professional qualifi cations of 
one researcher proposing Cs therapy for cancer have been challenged (Sa-
madani & Marcotte, 2004). Brewer (1984) and Sartori (1984b) speculated 
that the tumour-repressing activity was due to a specifi c rise of intracel-
lular pH in cancer cells, which slows down their rate of metabolism. Guns 
et al. (2005) recently confi rmed experimentally the rise of pH in certain 
tumour cells following Cs-treatment. Th e physiological or chemical basis 
for this shift  was not, however, discussed by the authors. One explanation 
for the eff ect could be that Cs+ as a strong base cation tends to increase the 
cytoplasmic strong ion diff erence (SID). Th is, in turn, decreases the cyto-
plasmic hydrogen ion concentration (Lindinger et al., 2005).
Th e toxic eff ects of Cs include ventricular arryhtmia (Jones et al., 2001; 
Saliba et al., 2001), salivation, diarrhoea and inhibition of motor activity 
(Bose & Pinsky, 1984; Fujii & Nomoto, 1987). In bone marrow of mice, 
high doses of caesium have been shown to have clastogenic eff ects (Ghosh 
et al., 1991) as well as induce micronucleation in polychromatic erythro-
cytes (Santos-Mello et al., 2001). Th ere are also reports about the develop-
mental toxicity of high doses of Cs (Messiha, 1994).
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5.3. Caesium assay methods 
Because of the low concentration of endogenous Cs in tissue and plasma 
samples, its analysis requires sensitive assay methods.  Neutron activation 
analysis (NAA) is based on the activation of stable istotopes with a neu-
tron fl ux and measurement of specifi c gamma emission of the daughter 
nuclide with a gamma spectrometer. Due to its exceptional sensitivity, 
NAA has been used widely in the study of Cs content in biological samples 
(Yamagata, 1962; Hock et al., 1975; Versieck et al., 1977; Kasperek et al., 
1979; Demmel et al., 1982; Gawlik et al., 1989; Kumar et al., 1989; Scholz, 
1990; Steiner, 1990; Iyengar et al., 2004). However, the method requires 
an experimental nuclear reactor which reduces considerably its practical 
applicability.
Mass spectrometry (MS) is another highly sensitive assay method, 
which utilizes the separation of accelerated ions in a magnetic fi eld. 
Schulten et al. (1978) developed a method based on fi eld desorption MS 
to investigate Cs in physiological fl uids. Inductively coupled plasma mass 
spectrometry (ICP-MS), a more recent method, has largely replaced NAA 
in the study of endogenous stable Cs in biological material (Vandecas-
teele et al., 1990; Corrigan et al., 1991; Krachler et al., 1999; Iyengar et al., 
2004). 
In atomic absorption spectrometry (AAS), the sample is atomized in a 
fl ame or some other heating device. Specifi c hollow-cathode lamps, plated 
with the metal under investigation (e.g. Cs), emit light of specifi c wave-
lengths, which is guided as a beam through the atomized sample. Th is light 
is absorbed by the atoms of the same metal in the atomized sample. One 
drawback of the method is that each element requires a specifi c lamp, com-
plicating multi-elemental analysis. Generally, AAS-applications are also 
far less sensitive than methods based on NAA or MS. AAS has been used 
mainly when studying the eff ects of added Cs in biological systems, either 
in basic research (Guns et al., 2005) or in cases of poisoning (Centeno et 
al., 2003). AAS-applications have also occasionally been used in the study 
of endogenous Cs (El-Yazigi et al., 1988). 
In principle, Cs concentration can also be investigated by using atomic 
emission spectrophotometry (AES). However, due to their relatively high 
detection limits, these methods have seldom been used in the study of 
biological samples. Kernan (1969, 1972) used fl ame photometry to deter-
mine the concentration of caesium in plasma and skeletal muscle follow-
ing chronic feeding of Cs. Earlier, Relman et al. (1957) had also used the 
method in a similar experiment, together with radioactive tracers (134Cs). 
In these experiments, the typical tissue Cs concentrations were well above 
10 mmol l-1 (1 mmol = 133 mg).
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Like photometry, nuclear magnetic resonance (NMR) is not a very sen-
sitive method, but it has a distinct advantage; it can be used to measure 
both extracellular and intracellular 133Cs in intact tissue and cells (Davis et 
al., 1988; Li et al., 1995). Th e method has been used in many experiments 
to study potassium transport mechanisms across cell membranes (Shehan 
et al., 1993; Schornack et al., 1997; Wellard & Adam, 2002). 
Radioactive tracers are frequently used in the study of the biological 
properties of Cs. At the beginning of the nuclear era, 137Cs (T½ = 30 years), 
separated from fi ssion products was the main tracer isotope used in such 
research. It was later replaced by 134Cs (T½ = 2.1 years), which can be pro-
duced by neutron activation of 133Cs. Both are strong gamma-emitters and 
are hence easily measured using gamma-spectroscopy. Cs isotopes with a 
short half-life, including 129Cs (T½ = 32 h), 131Cs (T½ = 9.7 days) and 134mCs 
(T ½ = 30 h), have been used as potassium analogues in experimental scin-
tigraphy (Rothman et al., 1974; Nishiyama et al., 1976; Turner et al., 1976; 
Gustafson et al., 1977 ). These experiments have not, however, lead to 
widespread use of radioactive Cs isotopes in practical scintigraphy.
In autoradiography, a radioactive tracer in the sample exposes a pho-
tographic fi lm pressed close to the sample. From the developed fi lm, body 
and tissue localization of the tracer can then be determined. Nelson et al. 
(1961) used autoradiography to study whole-body distribution of radioac-
tive Cs in mice. Autoradiography has also been used to examine the in-
tracellular distribution of Cs (Giese & Rekowski, 1970; Szentkuti & Giese, 
1973; Edelmann, 1980). 
Cs is an electron-dense element and therefore tends to be visible as such 
in transmission electron micrographs. Edelmann (1980) used this prop-
erty to study the distribution of Cs in Cs-loaded myocytes. 
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6. Aims of the study
- To develop a simple, inexpensive method to investigate the short-term  
 kinetics of plasma Cs. (I, II)
- To gather information about the short-term kinetics of plasma Cs in  
 goats and horses using the method developed (IV)
- To gather information about the short-term distribution of Cs in  
 order to explain its short-term plasma kinetics (III).
Aims of the study
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7. Materials and methods
7.1. Animals
Th e study protocols were approved by the Ethics Committee for animal ex-
perimentation at the University of Helsinki. Th e goats used were non-lac-
tating Finnish Landrace females, aged between 7 and 12 years and weigh-
ing between 43 and 56 kg. Th e horses were Standardbred mares and geld-
ings aged between 3 and 12 years and weighing between 408 and 524 kg.
7.2. Assay method for added stable caesium
Th e general assay procedure (II, IV) is based on competitive binding and 
is thus analogous to radioimmunoassay (RIA) (Yalow & Berson, 1960). In 
brief, 134Cs is added as a label to the sample containing stable Cs. Ammo-
nium-iron(III)-hexa cyano ferrate(II) (AFCF) is then added. Aft er incuba-
tion, AFCF-bound Cs is precipitated together with plasma proteins using 
trichloroacetic acid (TCA). Free Cs (both stable and radioactive) stays in 
solution. Th e precipitate is separated by centrifugation, and its 134Cs con-
tent is measured using a gamma-counter.
An essential element of the assay method is the eventual separation of 
AFCF-bound Cs and freely soluble Cs. Th us, the co-precipitation of AFCF 
and AFCF-bound Cs with plasma proteins should be quantitative. In addi-
tion, a minimum amount of free Cs should be precipitated in this process. 
To study these aspects, the behaviour of diff erent mixtures of AFCF, 
albu min and TCA were investigated (I). Following mixing of components, 
precipitation and centrifugation, the supernatant was decanted to another 
vial. Both precipitate and supernatant were studied for their AFCF-content. 
 Th e AFCF was of commercial grade (“Giese salt”), which contains 
30–35% ammonium chloride (by weight) in the dry product. Th e albumin 
solution was prepared from commercial dried bovine serum albumin. Th e 
solutions of TCA were prepared daily from a concentrated stock solution. 
Th e concentration of AFCF was measured in two diff erent ways. For 
concentrations above 10 mg l-1, absorption spectroscopy at 685 nm was 
used. For the measurement of lower concen trations, 134Cs-labelled AFCF 
(134Cs-AFCF) was prepared by incubating a dispersion of AFCF (10 mg l-l) 
with radioactive 134Cs tracer solution for three days. A standard gamma-
counter was used for quantitative measurement. 
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In Study I, the magnitude of the following parameters was varied in 
order to evaluate their eff ect to the precipitation process:
TCA concentration (2-50 g l-1)
AFCF concentration (0.5-10 mg l-1)
Albumin concentration (0.002-20 g l-1)
Temperature (0, 20, 37 oC)
Centrifugation speed and time (1000-4000 g, 5 – 20 min)
Washing of the precipitate 
Order and delay of adding components
Cation concentration (0.01 and 0.1 Eq l-1, ions H+, NH4+, Li+, Na+, K+, Cs+, Ca+, Mg+)
Based on the results of Study I, an assay procedure was developed (II) and 
tested (IV). Th e assay involves adding the following components:
  
a) Sample: heparinized blood plasma    0.1 ml
b) Standard: Cs solution ([CsCl] = 0-10000 μmol l-1)  0.1 ml
c) Tracer: 134Cs (7300 kBq l-1, [Cs] = 1 μmol l-1)  0.1 ml
d) Buff er: acidic calcium phosphate (0.1 mol l-1, pH 2.1)  0.5 ml
e) Binding agent: AFCF (12.5 mg l-1)   0.2 ml
Standard samples were prepared from plasma containing no added plasma 
Cs. Zero samples were standard samples with plain water ([CsCl] = 0) 
added at Stage b. Unknown samples contained an unknown amount of Cs 
from the beginning; hence, plain water was added at Stage b, as well. In 
blank samples, plain water was added instead of binding agent (AFCF) at 
Stage e. 
All plasma samples were taken from the animals within a short time pe-
riod (1-2 h). Standard, zero and blank samples were prepared from plasma 
taken from animals before they received a Cs-dose. Th e unknown samples 
were collected aft er this dose.
Aft er incubating the mixture for 24 h, AFCF and bound Cs were co-pre-
cipitated with plasma proteins by adding 1 ml of TCA (0.3 mol l-1). Aft er 
centrifugation (2500 g, 15 min), the supernatant was discarded and the 
count rate of the precipitate measured. Th e count rate of the blank sample 
was subtracted to reach the blank-corrected count rate. Dividing the blank-
corrected count rate of a sample with blank-corrected count rate in the 
zero sam ple gave the relative binding (= BR) of Cs. Th is value was between 
0 and 1, with zero indicating no binding and one indicating maxi mum 
binding.
When studying the interference of monovalent ions, other salt solutions 
were used instead of CsCl (Stage b). In addition, in order to eliminate the 
eff ect of endogenous plasma cations, a pure albumin solution (70 g l-1), 
instead of plasma, was used to precipitate AFCF (Stage a).  
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7.3. Plasma caesium kinetics 
Th e fi ve experimental goats in Study IV were all non-lactating females. Th e 
12 experimental horses, including both mares and geldings, were divided 
randomly into two groups (Group I and Group II), both with six individu-
als. Group I rested (standing) during the whole experiment. Group II trot-
ted for 40 min on a treadmill (inclination 3°, speed 5 m s-1).
From all animals, blood was evacuated for standard plasma samples, 
followed by an intravenous dose of CsCl (5 μmol kg-1 of live weight). 
Blood samples were collected at regular intervals into heparinized vials. 
In the group of running horses, heart rate was constantly monitored. In all 
horses, haematological parameters (Hb, PCV, WBC) and lactate concen-
tration was analyzed from whole blood samples. Th e concentrations of K, 
Na, Cl and Cs were determined from plasma. Plasma Cs was assayed using 
the method described above (Section 7.2).
Th e Cs concentration (μmol l-1) was divided by both 1.03 kg l-1 (density 
of plasma) and 5 μmol kg-1 (Cs dose) to reach a unitless value, henceforth 
called relative concentration (R). A two-phased exponential decay curve 
was fi tted to the data for plasma Cs relative concentration as a function of 
time, (see Section 7.5).
7.4. Tissue caesium distribution 
In Study III, six goats intravenously received a solution containing 134Cs 
as a Cs tracer and 51Cr-EDTA as an extracellular marker. Blood samples 
were collected at 2, 4, 6, 8, 10, 12, 15, 20, 25 and 30 min post-injection, 
and plasma was separated from cells by centrifugation. Aft er 30 min, the 
animals were euthanized and tissue samples collected.
Th e count rate of plasma and tissue samples was measured with a 
gamma-counter. Applying the appropriate corrections, the specifi c activi-
ties (Bq g-1) of both 134Cs and 51Cr in each sample were determined. Th ese 
were divided by the specifi c dose (total dose activity / animal weight) to 
reach a value for the relative concentration (R) of these isotopes, as de-
scribed above (Section 7.3). In Study III, the values are referred as relative 
activity concentration.
51Cr-EDTA does not enter cells. Dividing the relative concentration of 
51Cr-EDTA in a tissue sample by its extracellular relative concentration, 
approxi mated by its terminal plasma relative concentration, gives the ap-
proximate apparent extracellular fl uid fraction (E) in tissue. Using the pa-
rameters R and E, the apparent intracellular 134Cs relative concentration (I) 
in sample tissues was approximated. In addition, the total fraction of Cs 
dose accumulated in an organ (FCs) at termination was calculated. 
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7.5. Statistical analysis and curve fi tting
A t-test was used to determine signifi cance of diff erences between average 
values of two sets. In Study III, analysis of variance was used to test the 
signifi cance of diff erences in Cs concentration in diff erent muscle types.
In the assay of Cs (II, IV), the data for BR vs. Cs concentration were fi t-
ted on a curve of the form 
BR = 1/(1+10H(logC - logL))    (Eq. 1)
BR = relative binding of Cs (between 0 and 1) 
H = constant (‘Hill slope’)
C = Cs concentration 
L = Cs concentration at 50 % response, i.e. when BR = 1/2 
In Study II, the concentration of all samples was known. For each concen-
tration, there were six parallel samples. In Study IV, the Cs concentration 
of unknown samples was resolved using their BR and the standard curve 
according to Eq 1. 
In the study of plasma kinetics (III, IV), the following equations were 
applied:
R = K1 exp (-k1t) + K2 exp (-k2t)      (Eq. 2)
R = K’exp(-k’t)     (Eq. 3) 
R = relative concentration of Cs+
t = time elapsed aft er injection of dose (min)
K’, K1 and K2 = spans of diff erent phases
k’, k1 and k2 = rate constants of diff erent phases 
Eq. 2 was applied to data collected during a longer time span, starting from 
injection (III, IV), whereas the simpler Eq. 3 was used in Study IV to deter-
mine segmental rate constants during shorter periods.
Th e apparent rate of removal of Cs at instant t (kt) was estimated using 
the following equation:
- dR/R              k1K1exp(-k1t) + k2K2exp(-k2t)
kt =   ⎯⎯⎯   =   ⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯ (Eq. 4)  
               dt                     K1exp(-k1t)+K2exp(-k2t)
R = relative concentration of Cs+ 
t = time elapsed aft er injection of dose (min)
K1 and K2 = spans of diff erent phases resolved using Eq. 2
k1 and k2 = rate constants of diff erent phases resolved using Eq. 2
All curve fi tting was done using the computer program GraphPad Prism, 
version 3.03 for Windows (GraphPad Soft ware, San Diego, CA, USA, 
www.graphpad.com). 
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8. Results and discussion
8.1. Assay method for caesium
As described earlier (Section 7.2), the method is analogous to RIA. As 
the concentration of stable Cs increases, less 134Cs is bound by AFCF. Th e 
quantitative separation of Cs bound to AFCF and free Cs in solution is an 
essential element of this new assay method. Th e separation is achieved by 
co-precipitating AFCF and Cs bound to it together with plasma proteins, 
using TCA. Th e chemical background for this process is not clear. As spec-
ulated in Study I, the mutual affi  nity might be due to the diff erent charges 
of AFCF and protein precipitate in acidic surroundings.
Th e optimization of the precipitation process was the main aim of Study 
I. Th is involved, among others, experimenting with diff erent concent-
ration of components. Unless otherwise mentioned, the concentrations 
below refer to initial concentrations, i.e. the analytical concentrations of 
individual components in dispersion aft er mixing all components. 
Initial TCA concentrations of the order 50 g l-1 are typical when precipi-
tating proteins from blood plasma in clinical chemistry (Henry & Szust-
kiewicz, 1974). However, when precipitating AFCF-bound Cs+ ions, it is 
reasonable to keep the hydrogen ion concentration as low as possible to 
minimize the concentration of cations competing with Cs+.  In a system 
where the initial concentrations of albumin and AFCF were 0.5 g l-1 and 50 
mg l-1, respectively, an initial TCA concentration of 16 g l-1 was suffi  cient to 
reduce the absorption due to AFCF (685 nm) to well below 1% compared 
with the situation with no TCA. Increasing the TCA-concentration did not 
signifi cantly improve precipitation. However, below a TCA concentration 
of 16 g l-1, the precipitate no longer separated with simple centrifugation. 
Th us, in the actual assay, an initial concentration of 25 g l-1 (0.3 mol l-1) was 
used to err on the side of caution. 
In the actual assay (II, IV), the incubation concentration of AFCF was 
set at 2.5 mg l-1. At this level, 50% of tracer is absorbed in zero samples, 
which is the preferred level in RIA applications (Skelley et al., 1973). Using 
a 134Cs-labelled AFCF with an initial concentration of 2 mg l-1, the frac-
tion of activity remaining in supernatant aft er precipitation was around 
1.6% (I). Th e separation of the Cs-AFCF complex and soluble Cs is thus 
adequate also in the environment used in actual assay.
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An initial albumin concentration of 0.1 g l-1 was found to be suffi  cient to 
quantitatively bind AFCF at a level of 10 mg l-1. In the assay method, 0.1 ml 
of plasma was initially added. At precipitation, the volume was 2 ml. Hence, 
a 20-fold dilution of plasma occurred, indicating that the protein concen-
tration lies between 3 and 4 g l-1. Th is concentration is more than adequate 
for the binding of AFCF, but it has one minor drawback: this amount of 
precipitated protein binds around 3 % of total water and dissolved free Cs 
(I). However, since all plasma samples in an assay were collected from the 
same animal over a short period, the plasma protein concentration is not 
likely have varied much. Th e fraction of free Cs in precipitate is thus also 
similar in all samples, reducing the error caused by this “unspecifi c binding”. 
Increasing or decreasing the incubation temperature from room tem-
perature did not increase the yield of precipitated 134Cs-AFCF. Room tem-
perature was therefore used in the actual assay procedure. Centrifugal ac-
celerations above 2000 g and centrifugation times exceeding 10 min did 
not signifi cantly improve the separation of 134Cs-AFCF from dispersion. To 
be on the safe side, values of 2500g and 15 min were selected for the actual 
assay procedure.
Washing the precipitate once with TCA (20 g l-1) removed less than 
0.5% of the 134Cs. How much of this was desorbed 134Cs and how much in-
tact 134Cs-AFCF was not known. In any case, the amount was so low, that a pre-
cipitate wash during the actual assay procedure was deemed unnecessary.
When 134Cs-AFCF, albumin and TCA were added together just prior 
of centrifugation, around 1% of 134Cs activity remained in supernatant. 
When TCA was added 1 h later to a mixture of 134Cs-AFCF and albumin, 
the residual supernatant activity was somewhat higher, 1.6% (I). As before, 
it is diffi  cult to ascertain the form of the activity (134Cs-AFCF or 134Cs) in 
the supernatant. In the actual assay procedure Cs is bound to AFCF within 
an incubation period of 24 hours. Following precipitation, the curve of 
bound Cs vs. AFCF concentration had a typical sigmoid shape (Figure 1 
in II). When the AFCF concentration was 50 mg l-1, more than 98% of Cs 
was in the precipitate. Obviously, this long “delay” due to incubation in the 
actual assay procedure did not prevent quantitative removal of AFCF from 
dispersion.
In Study II, 0.2 μmol l-1 was the lowest sample concentration giving a 
signifi cantly diff erent count rate from zero samples (P<0.05, Table 2). In 
RIA, this lower detection limit is oft en used as a measure of sensitivity. 
Th is concentration also served as the lower cut off  value for further data 
processing.
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At low relative binding values (higher concentrations), their coeffi  cient 
of variation of relative binding tends to increase, increasing error (Table 2). 
For further data processing, the cut off  limit was set at 0.1 (10 %), thus ex-
cluding all sample concentrations above 200 μmol l-1. 
Between the two cut off  values (0.2-200 μmol l-1), the fi t of the data 
(logC vs. BR) to Eq. 1 (Section 7.5) was excellent; the coeffi  cient of determi-
nation (R2) for the standard curve was 0.9989, with 56 degrees of freedom. 
Based on the resolved equation parameters, a concentration estimate for 
each data point was made. For parallel samples, the mean and the coef-
fi cient of variation were calculated (Table 3).  Th e diff erence between the 
mean of estimates and actual concentration was used as a measure of ac-
curacy at that concentration. Th e coeffi  cient of variation of the estimates of 
parallel samples was used as an estimate of precision. 
Table 2. Count rates and relative binding of tracer 134Cs in precipitated AFCF aft er 
incubation with added Cs (n = 6 for each concentration) at the plasma concentrations 
indicated. Th e coeffi  cient of variation (CV) of relative binding at each concentration 
indicates the precision for the measurements of relative binding at that concentration. 
P shows the statistical signifi cance of the diff erence in count rate compared with the 
count rate in samples without added Cs (II)
Added Cs plasma 
concentration Count rate
Relative binding of 
134Cs tracer CV (%) P
(mmol l-1) (cpm) (average ± sd) (sd/average)
0 10293 ± 80 1 (by defi nition) 0.9   -   
0.05 10179 ± 96 0.988 ± 0.010 1.0 0.049
0.1 10136 ± 271 0.983 ± 0.029 3.0 0.204
0.2 10067 ± 154 0.976 ± 0.017 1.7 0.01
0.5   9516 ± 152 0.916 ± 0.016 1.8 <0.0001
1   8845 ± 124 0.844 ± 0.013 1.6 <0.0001
2   7929 ± 150 0.745 ± 0.016 2.2 <0.0001
5  6038 ±  90 0.540 ± 0.010 1.8 <0.0001
10  4678 ±  47 0.393 ± 0.005 1.3 <0.0001
20  3407 ±  47 0.256 ± 0.005 2.0 <0.0001
50  2373 ±  35 0.144 ± 0.004 2.6 <0.0001
100  1861 ±  44 0.089 ± 0.005 5.3 <0.0001
200  1549 ±  32 0.055 ± 0.003 6.2 <0.0001
500  1269 ±  25 0.025 ± 0.003 10.9 <0.0001
1000  1174 ±  19 0.015 ± 0.002 13.5 <0.0001
2000  1110 ±  22 0.008 ± 0.002 30.1 <0.0001
5000  1060 ±  28 0.002 ± 0.003 121 <0.0001
10000  1038 ±  21 0.000 ± 0.002 1373 <0.0001
Blank  1037 ±   9 0 (by defi nition)     
Total 19122 ± 170    
Background   175    
28 Results and discussion
Table 3. Comparison of actual and estimated Cs incubation concentrations using 
non-linear regression analysis (n = 6 for each concentration). Th e diff erence between 
mean of estimates and actual concentration indicates the accuracy of the method. Th e 
coeffi  cient of variation (CV) for concentration estimates indicates their precision (II)
Actual concentration Mean of estimates
Diff erence between 
mean of estimate and 
actual concentration
CV of 
estimates
(μmol l-1) (μmol l-1) (%) (%)
0.2 0.22 9.9 33.9
0.5 0.52 4.7 17.9
1 1.00 -0.4 9.8
2 1.87 -6.7 8.8
5 5.03 0.6 4.4
10 9.89 -1.1 2.5
20 20.7 3.7 3.2
50 49.1 -1.8 3.7
100 98.5 -1.5 7.3
200 200.2 0.1 9.5
As can be seen from Table 3, the precision of the method drops rapidly 
below a concentration of 1 μmol l-1. Th e most precise and accurate con-
centration range is 5-50 μmol l-1. When applying the method, the dose of 
Cs should be chosen to ensure that the plasma concentration is within the 
most reliable range.
In Study III, the plasma kinetics of intravenously dosed 134Cs was followed 
for 30 min. As can be seen in Table 4, the results are comparable with the 
results of Study IV, where stable Cs was used. 
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Table 4. Mean relative concentrations (R) (± SEM) of plasma Cs+ following an 
intravenous dose of Cs+ in diff erent groups of goats and horses (III, IV)
Minutes 
aft er 
Cs dose
Goats Horses (IV)
134Cs tracer 
(III)
Stable Cs 
(IV) Resting 
Exercising 
0-40 min 
R n R n R n R n
2 8.9 ± 0.4 6 9.3 ± 1.3 4 7.7 ± 0.4 6 6.8 ± 0.2 6
4 5.6 ± 0.2 6 6.3 ± 0.7 5 5.7 ± 0.2 6 5.1 ± 0.2 6
6 4.4 ± 0.2 6 4.7 ± 0.5 5 4.5 ± 0.2 6 4.0 ± 0.1 6
8 3.5 ± 0.2 6 4.0 ± 0.4 5 4.1 ± 0.1 6 3.2 ± 0.1 6
10 3.1 ± 0.2 6 3.2 ± 0.4 5 3.5 ± 0.2 6 2.7 ± 0.1 6
12 2.7 ± 0.2 6 2.8 ± 0.3 5 n/a n/a
15 2.3 ± 0.1 6 2.4 ± 0.3 5 2.6 ± 0.1 6 1.8 ± 0.1 6
20 1.8 ± 0.1 6 2.0 ± 0.3 5 2.2 ± 0.1 6 1.3 ± 0.1 6
25 1.6 ± 0.1 6 1.6 ± 0.2 5 1.8 ± 0.1 6 0.96 ± 0.06 6
30 1.4 ± 0.1 6 1.5 ± 0.2 5 1.5 ± 0.04 6 0.73 ± 0.07 6
40 n/a 1.2 ± 0.2 5 1.2 ± 0.1 6 0.41 ± 0.03 6
50 n/a 1.1 ± 0.2 5 1.0 ± 0.1 6 0.39 ± 0.05 6
60 n/a 0.93 ± 0.14 5 0.97 ± 0.08 6 0.30 ± 0.05 6
80 n/a 0.78 ± 0.09 5 n/a n/a
100 n/a 0.71 ± 0.11 5 n/a n/a
Th e ions H+, NH4+, Li+, Na+, K+, Cs+, Ca2+ and Mg2+ did not disturb the 
precipitation of AFCF (50 g l-1), even at the relatively high concentration of 
0.1 Eq l-1 (I). However, many monovalent cations interfere with the binding 
of Cs with AFCF (II). Th e ion concentration resulting in half-maximum 
binding of tracer (Cs+ 0.1 μmol l-1) increased as follows: Cs+ > Tl+ > Rb+ 
> NH4+ > K+ > Na+, indicating a decreasing affi  nity. Th is order of affi  nity 
is the same as the order of crystal ionic radii (Table 1). Th e range in the 
binding affi  nity was extensive, with Cs having a half-maximum binding 
concentration at 0.45 μmol l-1 and Na at 160 mmol l-1.  Li+, Mg2+ and Ca2+ 
had no apparent affi  nity towards AFCF, even at concentrations around 1 
mol l-1.
Th e half-maximum binding concentration value for Cs was about 30% 
higher in plasma than in pure albumin solution. Th e most likely reason is 
plasma Na, which reduces the relative binding of 134Cs by around 20% un-
der the experimental conditions. Rb plasma concentrations between 1 and 
11 μmol l-1 are reported in the literature (Versieck et al., 1977). Th e high-
est value would reduce the relative binding of 134Cs by approximately 10% 
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under the experimental conditions. However, since all plasma samples, in-
cluding those used to prepare the standard samples, were taken from the 
same animal within a short period, the concentration of these interfering 
ions is not likely to have varied, thus not causing signifi cant bias. 
8.2. Short-term plasma kinetics of caesium
Intravenously dosed stable Cs disappears from blood plasma very rapidly, 
as illustrated in Table 4. Between 2 and 30 min aft er intravenous dose, 
the extracellular Cs level decreased by more than 80% in both goats and 
horses. During the next 30-min time span (30-60 min aft er injection) the 
reduction in plasma Cs concentration was around 40%. Between 60 and 
100 min aft er injection, the plasma Cs concentration dropped by 25 %. 
Th ese results are in general accordance with graphical data on dogs pre-
sented by Poe (1972). 
At 30 min, around 14% of the original Cs dose is estimated to remain in 
the extra cellular space (III). Assuming a rapid equilibrium between plasma 
and interstitial fl uid, the fraction of the dose remaining in extracellular 
fl uid at diff erent instances can be estimated from the plasma concentration 
data in Study IV. Th ese estimates are presented in Table 5.
Table 5. Estimated fraction of Cs in goat extracellular fl uid and the apparent 
rate (Section 7.5) for removal of Cs from blood plasma following an intrave-
nous dose of Cs. 
Minutes aft er 
intravenous 
Cs dose
% of Cs dose in 
extracellular space
Apparent rate (kt) for 
removal of Cs from 
plasma (min-1)
2 87 0.121
10 30 0.085
20 19 0.040
30 14 0.019
40 11 0.013
50 9.8 0.011
60 8.7 0.011
80 7.3 0.011
100 6.6 0.011
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By applying Eq. 2 (Section 7.5) to data from Table 4, diff erent kinetic pa-
rameters can be resolved for both goats and horses. Th ese parameters were 
fairly similar for the two species, with signifi cant diff erences only in the 
value of K1 (Table 6). Using goat data from the whole measured time span 
(2-100 min) resulted in slightly diff erent kinetic values (K1 = 8.3 ± 1.0, K2 = 
1.9 ± 0.3, k1 = 0.15 ± 0.3 min-1, k2 =0.011 ± 0.0023). Applying Eq. 4 (Section 
7.5) to these values, the apparent rate of removal of Cs (kt) at any instat can 
be estimated. As shown in Table 5, this rate falls rapidly during the fi rst 30 
min. Rate constants with a small absolute value can be interpreted as the 
fraction of removed component per unit time. For example, a rate constant 
of 0.01 min-1 means that the concentration of the component reduces ap-
proximately 1% each minute.  
Table 6. Mean kinetic parameters (± SEM) for the curve describing the removal of 
plasma Cs+ in resting hor ses and goats. Th e parameters were calculated by applying Eq. 
2 (Section 7.5) to relative concentration data between 2 and 60 min.
 Goats Horses p
 
K1 9.6 ± 0.8 6.5 ± 0.5 0.0052
K2 2.4 ± 0.2 2.3 ± 0.3 0.95
k1 (min-1) 0.2 ± 0.02 0.15 ± 0.002 0.11
k2 (min-1) 0.016 ± 0.002 0.016 ± 0.003 0.89
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8.3.  Short-term distribution of caesium
Th e rapid initial removal of plasma Cs raised the question: where does it 
go? As discussed before (see Section 5.2), the excretion of Cs is too slow to 
aff ect signifi cantly the short-term kinetics of Cs. Th us, the drop in plasma 
Cs is almost solely due to distribution to diff erent tissues. Th e overall organ 
distribution of 134Cs at 30 min aft er an intravenous dose (III) is displayed 
in Table 7. For comparison, the same table presents the plasma-organ and 
organ-plasma transfer coeffi  cients used in the Leggett model (Leggett et 
al., 2003). 
Table 7. Comparison of the distribution of 134Cs in major organs in goat 30 minutes 
aft er dose and estimated transfer coeffi  cients of Cs in diff erent organs of man.
Cs contenta 
(% of total dose)
Estimated transfer 
coeffi  cient from 
plasma to organb
Estimated transfer 
coeffi  cient from 
organ to plasmab
Kidney 13.0 67 32
Skeletal muscle 13.8 30 0.075
Gastrointestinal tract tissue 13.8 53 8.2
Gastrointestinal tract contents  7.9 5.5c 28d
Liver  4.7 19 2.2
Heart  3.3 14 8.1
Lungs  2.2 4.4 1.5
Salivary gland  1.8 n/a n/a
Pancreas  0.8 1.8 1.7
Spleen  0.5 5.3 5.0
Total recovered  62.1
aStudy III
bLeggett et al.(2003)
csum of values for stomach, small intestine and large intestine contents
dsmall intestine contents
Aft er 30 minutes, the gastrointestinal tract, kidneys and skeletal muscle 
have incorporated a large fraction of the injected dose. Th e same tissues 
also have the greatest diff erence between the plasma-organ and organ-
plasma transfer coeffi  cients in the Leggett model (Leggett et al., 2003). 
Th ese locations are thus good candidates when contemplating the destiny 
of rapidly removed Cs during the fi rst 20-30 min aft er dosing. However, 
since a large fraction (38%) of the initial dose was not recovered quanti-
tatively aft er 30 minutes (Table 7), other possibilities must be considered. 
According to Study III, the specifi c activity of most connective tissue sam-
ples 30 min aft er the intravenous dose of 134Cs is more than twice as high as 
that of most skeletal muscle samples. Ubiquitous connec tive tissue is there-
fore a good candidate for the unrecovered fraction of the initial Cs dose 
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in Study III. Its proteins and glycos ami no glycans have a negative charge 
in physiological surroundings. Th us, it is likely that the initial mechanism 
of incorporation of Cs into connective tissue is extracellular ion exchange, 
rather than transport into intracellular space. Th is mechanism has been 
suggested earlier to explain the high initial affi  nity of cartilage towards Cs 
(Nelson et al., 1961). Leggett et al. (2003) did not include this phenomenon 
in their pharmacokinetic model due to insuffi  cient quantitative informa-
tion (personal communication).  
8.4. Effect of exercise on plasma caesium
Exercise aff ects plasma Cs kinetics, as can be seen in Table 4. As presented 
in Study IV, the rate constant k2 is twice as high in the exercising group 
(0.057 ± 0.005 min-1) as in the resting group (0.027 ± 0.003 min-1). Th e 
diff erences in other parameters are not signifi cant. Exercise thus seems 
to have an eff ect only on the slower compartment when applying a two-
compartment model to the data. Th is is in accordance with the fi ndings 
that non-muscular tissue in goats is responsible for more than 80% of the 
removal of Cs from the bloodstream during the fi rst 30 min (Table 7). Th e 
larger rate constant k1, which is unaff ected by exercise, is likely to refl ect the 
rate of fast incorporation, for which mainly non-muscular tissue is respon-
sible. With increased intracellular concentration, the rate of incorporation 
decreases and the rate of decorporation increases. As non-muscular tissues 
approach steady state with respect to Cs, the slower incorporation of Cs 
into skeletal muscle starts to play a major role in gross plasma kinetics. 
Th e mechanism responsible for the increase of k2 during exercise re-
mains obscure, but a plausible explanation is the increase in the activity of 
muscle Na,K-ATPase. Na,K-ATPase is known to be the major transporter 
of Cs into muscle cells (Beauge & Sjodin, 1968; Dorup & Clausen, 1994). 
Exercise is also known to be a very effective stimulant of muscle Na,K-
ATPase (Clausen, 2003).
In study IV, the rate or Cs removal from plasma returns to resting level 
within 10 min aft er the end of exercise (Figure 1 in IV). Assuming that 
Na,K-ATPase is the major remover of Cs from blood, this would mean that 
this active transport protein responds rapidly to changes in muscle activity, 
just like suggested by Lindinger (1995). However, in Study IV the level of 
plasma K dropped signifi cantly from an already hypokalaemic level even 
later than 10 min aft er cessation of exercise (Figure 2 in IV). Th ese diff er-
ences in post-exercise plasma kinetics of Cs and K would be an interesting 
topic for future research.
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8.5. Future prospects
As indicated above, determining the rate of Cs removal from plasma by ap-
plying added Cs might be one means of gaining information about Na,K-
ATPase in-vivo.  Measurement of plasma kinetics using numerous time 
points from the beginning of application of Cs might be superfl uous. A few 
measurements between 20 and 40 minutes and applying Eq. 3 (Section 7.5) 
could be enough to get an estimate for the segmental rate constant k’, which 
has a value very close to k2 (Study IV). 
One drawback in such experiments is the use of exogenous stable Cs. 
Although modern assay methods allow for doses that have absolutely no 
physiological eff ect, the dosing of an exogenous substance might cause 
ethical problems, especially when investigating human biology. Th ese 
problems might be circumvented by measuring the level of endogenous Cs 
in plasma before and aft er procedures that increase or decrease the activity 
of Na,K-ATPase. Needless to say, for these experiments, the assay method 
described in this thesis (Section 8.1) is not sensitive enough. But with ap-
propriate modern assay methods, like ICP-MS, more information about 
the short-term kinetics of Cs in diff erent physiological states can be gained. 
As mentioned above, this might be useful in the study of Na,K-ATPase 
activity in vivo.
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9. Conclusions
In a mixture of water, caesium ions (Cs+) and the colloidal Cs binder am-
monium-iron(III)-hexa cyano ferrate(II) (AFCF), the amount of AFCF-
bound Cs aft er a set incubation period is a function of Cs concentration 
in the system. AFCF and the Cs bound to it can be precipitated together 
with albumin and other plasma proteins using trichloroacetic acid, leav-
ing the unbound Cs fraction in the supernatant. If radioactive Cs (134Cs) is 
added to the incubation mixture, the activity of the precipitate depends on 
the total incubation concentration of Cs. Th us the concentration of added 
Cs in plasma samples can be determined by adding fi xed amounts of 134Cs 
and AFCF, incubating them for a set period (24 h), co-precipitating AFCF-
bound Cs with proteins and measuring the radioactivity of the precipitate. 
For this new assay method, the lower concentration limit of quantitative 
measurements is around 1 μmol l-1.  
Th e method is limited to the measurement of added Cs in blood plasma, 
and due to its low sensitivity is not suitable for the measurement of endog-
enous Cs in blood or other tissues. However, it provides a simple way of 
measuring short-term plasma kinetics of Cs following non-toxic Cs doses. 
Th us, it may be useful to researchers who do not have access to more sen-
sitive methods, such as nuclear activation analysis or mass spectrometry. 
Here, the new method developed was used to determine the short-term 
kinetics of Cs of blood plasma in goats and horses. 
In both horses and goats, the rate of removal of Cs from blood plasma 
decreases very rapidly aft er an intravenous dose. Th e apparent rate initially 
exceeds 0.1 min-1 both in goats and horses, but drops to a value well under 
0.02 min-1 at 40 min aft er dosing. Between 2 and to 40 min, the plasma 
kinetics of Cs can be approximated with a two-phase exponential decay 
curve. According to the literature, the sodium-potassium pump (Na, K-
ATPase) has a central role in the uptake of Cs from the extracellular space 
into cells. Tissues with known high Na, K-ATPase activity were found to 
contain a high concentration of Cs 30 min aft er dosing. Exercise, a known 
stimulant of muscle Na,K-ATPase, also increased considerably the removal 
of Cs from blood. 
Conclusions
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During the fi rst 30 min aft er the intravenous dose, connective tissue, 
especially cartilage, incorporates Cs at a faster rate than most skeletal mus-
cle. Connective tissue consists mostly of extracellular components, which 
contain a large amount of negatively charged groups.  Th us it is reasonable 
to assume that ion-exchange processes contribute to the rapid initial phase 
of Cs removal. 
Th e connection between Na,K-ATPase activity and short-term plasma 
Cs kinetics may open up possibilities for the use of intravenously dosed Cs 
in the study of Na,K-ATPase activity in vivo. 
Conclusions
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